CIK 0001563880 · Non-accelerated filer<br>Smaller reporting company
Trevi Therapeutics, Inc.
Sign in to watch- Ticker
- TRVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450834299
- Phone
- 203-304-2499
- Business address
- 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $595,806
- in 1 filing, $596K under 10b5-1 plans
Net −$595,806. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-29 | SCIASCIA THOMAS Chief Scientific Officer | Sale | −53,368 | $2.55 | $136K | 214,433 |
| 2024-05-29 | SCIASCIA THOMAS Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −59,354 | 0 | ||
| 2024-05-22 | Delfini Lisa Chief Financial Officer | Option exercise | +16,043 | $0.51 | $8K | 57,629 |
| 2024-05-22 | Delfini Lisa Chief Financial Officer | Sale | −4,350 | $2.64 | $11K | 53,279 |
| 2024-05-22 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) | −16,043 | 48,125 | ||
| 2024-05-20 | GOOD JENNIFER L President & CEO | Option exercise | +25,037 | $2.19 | $55K | 238,350 |
| 2024-05-20 | GOOD JENNIFER L President & CEO | Sale | −25,037 | $2.86 | $72K | 213,313 |
| 2024-05-20 | GOOD JENNIFER L President & CEO | Option exercise · Stock Option (right to buy) | −25,037 | 33,189 | ||
| 2024-05-10 | GOOD JENNIFER L President & CEO | Option exercise | +4,578 | $2.19 | $10K | 217,891 |
| 2024-05-10 | GOOD JENNIFER L President & CEO | Sale | −4,578 | $2.90 | $13K | 213,313 |
| 2024-05-10 | GOOD JENNIFER L President & CEO | Option exercise · Stock Option (right to buy) | −4,578 | 58,226 | ||
| 2024-02-15 | Galletta Christopher See Remarks | Grant or award · Stock Option (right to buy) | +28,500 | 28,500 | ||
| 2024-02-15 | Simon Farrell Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2024-02-15 | Clark David J Chief Medical Officer | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2024-02-15 | GOOD JENNIFER L President & CEO | Grant or award · Stock Option (right to buy) | +630,000 | 630,000 | ||
| 2024-02-15 | SCIASCIA THOMAS Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2024-02-15 | Delfini Lisa Chief Financial Officer | Grant or award · Stock Option (right to buy) | +175,000 | 175,000 | ||
| 2023-10-11 | Delfini Lisa Chief Financial Officer | Option exercise 10b5-1 | +2,292 | $0.51 | $1K | 36,686 |
| 2023-10-11 | Delfini Lisa Chief Financial Officer | Sale 10b5-1 | −785 | $2.02 | $2K | 35,901 |
| 2023-10-11 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,292 | 64,168 |
Page 6 of 9 · 179 trades